OrbiMed’s Rhythm Pharmaceuticals RYTM Stock Holding History

OrbiMed’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.9M	Buy	322,900 +8,800	+3%	+$796K	0.66%	44
2026 Q1	$27.3M	Buy	314,100 +74,300	+31%	+$7.23M	0.54%	51
2025 Q4	$25.7M	Buy	239,800 +24,648	+11%	+$2.61M	0.52%	54
2025 Q3	$21.7M	Sell	215,152 -33,360	-13%	-$3.1M	0.51%	52
2025 Q2	$15.7M	Sell	248,512 -131,488	-35%	-$8.05M	0.39%	47
2025 Q1	$20.1M	Sell	380,000 -20,000	-5%	-$1.11M	0.48%	44
2024 Q4	$22.4M	Sell	400,000 -35,900	-8%	-$1.98M	0.46%	49
2024 Q3	$22.8M	Sell	435,900 -268,942	-38%	-$12.9M	0.41%	60
2024 Q2	$28.9M	Hold	704,842	–	–	0.57%	47
2024 Q1	$30.5M	Buy	704,842 +168,200	+31%	+$7.36M	0.56%	49
2023 Q4	$24.7M	Sell	536,642 -47,000	-8%	-$1.48M	0.49%	58
2023 Q3	$13.4M	Buy	+583,642	New	+$13.1M	0.28%	73
2019 Q3	–	Sell	-787,300	Closed	-$17.3M	–	134
2019 Q2	$17.3M	Hold	787,300	–	–	0.27%	75
2019 Q1	$21.6M	Sell	787,300 -141,200	-15%	-$4.06M	0.33%	71
2018 Q4	$25M	Sell	928,500 -112,853	-11%	-$3.12M	0.46%	62
2018 Q3	$30.4M	Sell	1,041,353 -1,023,647	-50%	-$32.3M	0.37%	71
2018 Q2	$64.6M	Sell	2,065,000 -836,295	-29%	-$22.9M	0.77%	43
2018 Q1	$57.7M	Hold	2,901,295	–	–	0.72%	48
2017 Q4	$43.5M	Buy	+2,901,295	New	+$76.7M	0.55%	56

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed's RYTM Position: Q2 2026 in Review

OrbiMed increased its Rhythm Pharmaceuticals (RYTM) stake by 2.8% in Q2 2026, buying an estimated $796K and bringing the position to 322,900 shares worth $35.9M. The position accounts for 0.66% of the portfolio, ranked #44.

OrbiMed first reported a position in RYTM in Q4 2017 and has held it in 19 quarters since. The position peaked at $64.6M in Q2 2018. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

OrbiMed held 322,900 shares of Rhythm Pharmaceuticals worth $35.9M as of Q2 2026.
OrbiMed bought 8,800 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $796K.
Rhythm Pharmaceuticals made up 0.66% of OrbiMed's portfolio in Q2 2026, its #44 holding.
OrbiMed first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
OrbiMed's Rhythm Pharmaceuticals position peaked at $64.6M in Q2 2018.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.